



## Development of Influenza Vaccine

Tooru Tanzawa/DAIICHI SANKYO COMPANY, LIMITED

**#Aim:** The aim of this project is to develop a vaccine for highly pathogenic avian influenza (HPAI) using LNP-mRNA technology. This initiative is part of the broader effort to enhance pandemic preparedness and response capabilities.

**#Progress:** The project is currently focused on the formulation development, clinical trial manufacturing, and conducting both non-clinical and clinical trials to establish proof-of-concept for the LNP-mRNA-HPAI vaccine. These trials are essential to ensure the vaccine's safety and efficacy before it can be widely distributed.

**#Task:** Key tasks include establishing the manufacturing process for the LNP-mRNA-HPAI vaccine, producing clinical trial materials, and conducting comprehensive clinical trials. Additionally, the project involves continuous monitoring and optimization of the vaccine formulation to enhance its stability and effectiveness.

**#Goal:** The primary goal is to establish a reliable manufacturing process and obtain proof-of-concept for the LNP-mRNA-HPAI vaccine through clinical trials. This includes achieving regulatory approvals and ensuring the vaccine meets all safety and efficacy standards.

**#Expected outcomes:** The successful development of this vaccine is expected to significantly enhance pandemic preparedness by providing a rapid response capability for HPAI outbreaks. The LNP-mRNA technology is anticipated to offer higher efficacy compared to traditional vaccines. Furthermore, the established manufacturing platform can be utilized for future infectious disease outbreaks, ensuring rapid response capabilities. This project aims to contribute to public health by providing a more efficient and effective vaccination strategy.